Erlotinib treatment promoted modest enhancement of radiation effects in canine OSA cells, and showed activity as a single agent, indicating a possible role of EGFR inhibition in the treatment of a subset of OSA patients. This evidence concerns the gene EGFR and obstructive sleep apnea syndrome.